Ignite Creation Date:
2025-12-24 @ 10:07 PM
Ignite Modification Date:
2025-12-25 @ 7:43 PM
Study NCT ID:
NCT07214935
Status:
COMPLETED
Last Update Posted:
2025-11-13
First Post:
2025-10-08
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A TQT Study of Effect of M2951 on Cardiac Repolarization
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077266', 'term': 'Moxifloxacin'}, {'id': 'C000632111', 'term': 'evobrutinib'}], 'ancestors': [{'id': 'D024841', 'term': 'Fluoroquinolones'}, {'id': 'D042462', 'term': '4-Quinolones'}, {'id': 'D015363', 'term': 'Quinolones'}, {'id': 'D011804', 'term': 'Quinolines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'service@emdgroup.com', 'phone': '+49-6151-72-5200', 'title': 'Communication Center', 'organization': 'Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Up to 3 months', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition', 'otherNumAtRisk': 32, 'deathsNumAtRisk': 32, 'otherNumAffected': 8, 'seriousNumAtRisk': 32, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': '400 mg Moxifloxacin', 'description': 'Participants received single oral dose of Moxifloxacin 400mg in treatment period 1, 2, 3 or 4under fasted condition', 'otherNumAtRisk': 32, 'deathsNumAtRisk': 32, 'otherNumAffected': 5, 'seriousNumAtRisk': 32, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': '45 mg Evobrutinib', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition', 'otherNumAtRisk': 31, 'deathsNumAtRisk': 31, 'otherNumAffected': 8, 'seriousNumAtRisk': 31, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': '225 mg Evobrutinib', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition', 'otherNumAtRisk': 32, 'deathsNumAtRisk': 32, 'otherNumAffected': 5, 'seriousNumAtRisk': 32, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Atrioventricular block second degree', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Ventricular extrasystoles', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Ventricular tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Periorbital haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Blood pressure increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Lipase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 31, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'meddra 25.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': "Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib", 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.62', 'groupId': 'OG000', 'lowerLimit': '-2.15', 'upperLimit': '-1.09'}, {'value': '-2.28', 'groupId': 'OG001', 'lowerLimit': '-3.63', 'upperLimit': '-0.93'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Baseline and from 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours', 'description': 'A linear mixed-effects model was used to analyze the relationship between evobrutinib and MSC2729909A concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted over the clinical concentration range and at concentrations corresponding to the observed geometric mean Cmax following administration of 45 mg and 225 mg evobrutinib. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.', 'unitOfMeasure': 'milliseconds', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The ECG analysis set includes all participants who had a baseline Holter ECG in triplicate and at least one post baseline Holter ECG in triplicate with a time-matched concentration'}, {'type': 'SECONDARY', 'title': "Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Moxifloxacin", 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '12.2', 'groupId': 'OG000', 'lowerLimit': '10.3', 'upperLimit': '14.1'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'From 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours', 'description': 'A linear mixed-effects model was used to analyze the relationship between moxifloxacin concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.', 'unitOfMeasure': 'milliseconds', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants who had a baseline Holter ECG in triplicate and at least one post baseline Holter ECG in triplicate with a time-matched concentration.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to 3 months', 'description': 'An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.Therefore, an AE can be any unfavorable and unintended sign (including an abnormallaboratory finding), symptom, or disease temporally associated with the use of amedicinal product, regardless if it is considered related to the medicinal product.Serious AE: AE that resulted in any of the following outcomes: death; life threatening;persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization;congenital anomaly/birth defect. TEAEs are defined as AEs that were reported orworsened on or after start of study drug dosing through the Safety Follow-up Visit.TEAEs included both serious TEAEs and non-serious TEAEs. Treatment related AEs:reasonably related to the study drug/study treatment.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg n treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg n treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to 3 months', 'description': 'Severity of adverse events (AE) were assessed by the investigator. The Investigator assessed the intensity of each AE and SAE reported during the study and assigned it to 1 of the following categories:\n\n1\\. Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. 2. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 3. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Number of participants with severe adverse events were reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Abnormalities From Baseline in Safety Laboratory Tests', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 mg in Period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 29', 'description': 'The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities from baseline were reported. Clinically Significance was decided by investigator.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Abnormalities From Baseline in Vital Signs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 29', 'description': 'Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Changes From Baseline in Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 29', 'description': 'The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities were reported. Clinically significance was decided by investigator.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) of Evobrutinib', 'denoms': [{'units': 'Participants', 'counts': [{'value': '30', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '249', 'spread': '38.4', 'groupId': 'OG000'}, {'value': '1420', 'spread': '37.5', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.', 'unitOfMeasure': 'hour*nanogram/milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Evobrutinib', 'denoms': [{'units': 'Participants', 'counts': [{'value': '30', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '248', 'spread': '38.4', 'groupId': 'OG000'}, {'value': '1420', 'spread': '37.5', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.'}, {'type': 'SECONDARY', 'title': 'Maximum Observed Plasma Concentration (Cmax) of Evobrutinib', 'denoms': [{'units': 'Participants', 'counts': [{'value': '30', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '123', 'spread': '45.8', 'groupId': 'OG000'}, {'value': '670', 'spread': '51.3', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.'}, {'type': 'SECONDARY', 'title': 'Time to Reach Maximum Blood Concentration (Tmax) of Evobrutinib', 'denoms': [{'units': 'Participants', 'counts': [{'value': '30', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '0.500', 'groupId': 'OG000', 'lowerLimit': '0.267', 'upperLimit': '2.02'}, {'value': '0.500', 'groupId': 'OG001', 'lowerLimit': '0.250', 'upperLimit': '2.03'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.', 'unitOfMeasure': 'hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.'}, {'type': 'SECONDARY', 'title': 'Apparent Terminal Half-life (t1/2) of Evobrutinib', 'denoms': [{'units': 'Participants', 'counts': [{'value': '30', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '1.32', 'spread': '22.7', 'groupId': 'OG000'}, {'value': '2.09', 'spread': '33.8', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.', 'unitOfMeasure': 'hours', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.'}, {'type': 'SECONDARY', 'title': 'Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) Of Moxifloxacin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '30', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '19600', 'spread': '19.6', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.'}, {'type': 'SECONDARY', 'title': 'Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '30', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '2000', 'spread': '30.3', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Moxifloxacin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '30', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '24900', 'spread': '19.8', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.', 'unitOfMeasure': 'h*ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.'}, {'type': 'SECONDARY', 'title': 'Time to Reach Maximum Blood Concentration (Tmax) of Moxifloxacin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '30', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'categories': [{'measurements': [{'value': '1.50', 'groupId': 'OG000', 'lowerLimit': '0.250', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.', 'unitOfMeasure': 'hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.'}, {'type': 'SECONDARY', 'title': 'Effect of Evobrutinib on ECG Parameters: ECG Mean Heart Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '58.1', 'spread': '8.38', 'groupId': 'OG000'}, {'value': '58.6', 'spread': '7.38', 'groupId': 'OG001'}, {'value': '58.7', 'spread': '7.90', 'groupId': 'OG002'}, {'value': '57.9', 'spread': '7.61', 'groupId': 'OG003'}]}]}, {'title': '15 Minutes Post-dose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '3.26', 'groupId': 'OG000'}, {'value': '1.3', 'spread': '3.83', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '2.58', 'groupId': 'OG002'}, {'value': '0.8', 'spread': '2.65', 'groupId': 'OG003'}]}]}, {'title': '30 Minutes Post-dose', 'categories': [{'measurements': [{'value': '0.0', 'spread': '3.43', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '3.26', 'groupId': 'OG001'}, {'value': '1.6', 'spread': '3.57', 'groupId': 'OG002'}, {'value': '0.7', 'spread': '2.98', 'groupId': 'OG003'}]}]}, {'title': '1 Hour Post-dose', 'categories': [{'measurements': [{'value': '1.7', 'spread': '3.68', 'groupId': 'OG000'}, {'value': '1.0', 'spread': '4.00', 'groupId': 'OG001'}, {'value': '2.6', 'spread': '3.80', 'groupId': 'OG002'}, {'value': '3.2', 'spread': '4.10', 'groupId': 'OG003'}]}]}, {'title': '1.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '1.7', 'spread': '3.26', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '3.60', 'groupId': 'OG001'}, {'value': '3.0', 'spread': '3.48', 'groupId': 'OG002'}, {'value': '3.9', 'spread': '4.03', 'groupId': 'OG003'}]}]}, {'title': '2 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '3.10', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '2.21', 'groupId': 'OG001'}, {'value': '3.6', 'spread': '4.76', 'groupId': 'OG002'}, {'value': '2.8', 'spread': '3.05', 'groupId': 'OG003'}]}]}, {'title': '2.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '4.04', 'groupId': 'OG000'}, {'value': '0.7', 'spread': '3.73', 'groupId': 'OG001'}, {'value': '1.9', 'spread': '4.22', 'groupId': 'OG002'}, {'value': '1.2', 'spread': '3.64', 'groupId': 'OG003'}]}]}, {'title': '3 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '4.43', 'groupId': 'OG000'}, {'value': '-0.0', 'spread': '3.28', 'groupId': 'OG001'}, {'value': '2.4', 'spread': '3.63', 'groupId': 'OG002'}, {'value': '1.9', 'spread': '4.13', 'groupId': 'OG003'}]}]}, {'title': '4 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.8', 'spread': '3.67', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '3.54', 'groupId': 'OG001'}, {'value': '2.7', 'spread': '6.52', 'groupId': 'OG002'}, {'value': '2.7', 'spread': '4.03', 'groupId': 'OG003'}]}]}, {'title': '6 Hour Post-dose', 'categories': [{'measurements': [{'value': '6.6', 'spread': '6.42', 'groupId': 'OG000'}, {'value': '6.1', 'spread': '4.85', 'groupId': 'OG001'}, {'value': '7.8', 'spread': '4.84', 'groupId': 'OG002'}, {'value': '9.3', 'spread': '5.53', 'groupId': 'OG003'}]}]}, {'title': '8 Hour Post-dose', 'categories': [{'measurements': [{'value': '4.2', 'spread': '5.85', 'groupId': 'OG000'}, {'value': '2.3', 'spread': '5.29', 'groupId': 'OG001'}, {'value': '5.5', 'spread': '4.24', 'groupId': 'OG002'}, {'value': '5.2', 'spread': '5.30', 'groupId': 'OG003'}]}]}, {'title': '12 Hour Post-dose', 'categories': [{'measurements': [{'value': '1.3', 'spread': '5.36', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '4.63', 'groupId': 'OG001'}, {'value': '2.6', 'spread': '5.62', 'groupId': 'OG002'}, {'value': '0.7', 'spread': '4.75', 'groupId': 'OG003'}]}]}, {'title': '16 Hour Post-dose', 'categories': [{'measurements': [{'value': '3.5', 'spread': '5.91', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '5.73', 'groupId': 'OG001'}, {'value': '4.6', 'spread': '5.25', 'groupId': 'OG002'}, {'value': '5.6', 'spread': '5.16', 'groupId': 'OG003'}]}]}, {'title': '24 Hour Post-dose', 'categories': [{'measurements': [{'value': '6.0', 'spread': '7.88', 'groupId': 'OG000'}, {'value': '2.6', 'spread': '5.62', 'groupId': 'OG001'}, {'value': '4.3', 'spread': '5.38', 'groupId': 'OG002'}, {'value': '5.3', 'spread': '5.69', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of Heart rate was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.', 'unitOfMeasure': 'beats/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Effect of Evobrutinib on ECG Parameters: RR Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '1057.4', 'spread': '146.41', 'groupId': 'OG000'}, {'value': '1044.0', 'spread': '139.39', 'groupId': 'OG001'}, {'value': '1043.4', 'spread': '144.03', 'groupId': 'OG002'}, {'value': '1056.1', 'spread': '140.61', 'groupId': 'OG003'}]}]}, {'title': '15 Minutes Post-dose', 'categories': [{'measurements': [{'value': '-14.8', 'spread': '60.09', 'groupId': 'OG000'}, {'value': '-24.4', 'spread': '63.48', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '45.64', 'groupId': 'OG002'}, {'value': '-13.8', 'spread': '54.73', 'groupId': 'OG003'}]}]}, {'title': '30 Minutes Post-dose', 'categories': [{'measurements': [{'value': '-4.2', 'spread': '65.10', 'groupId': 'OG000'}, {'value': '-4.9', 'spread': '55.65', 'groupId': 'OG001'}, {'value': '-26.6', 'spread': '66.04', 'groupId': 'OG002'}, {'value': '-11.3', 'spread': '48.52', 'groupId': 'OG003'}]}]}, {'title': '1 Hour Post-dose', 'categories': [{'measurements': [{'value': '-30.2', 'spread': '72.81', 'groupId': 'OG000'}, {'value': '-17.0', 'spread': '60.28', 'groupId': 'OG001'}, {'value': '-40.3', 'spread': '62.87', 'groupId': 'OG002'}, {'value': '-47.3', 'spread': '58.95', 'groupId': 'OG003'}]}]}, {'title': '1.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-34.4', 'spread': '65.46', 'groupId': 'OG000'}, {'value': '-17.2', 'spread': '59.43', 'groupId': 'OG001'}, {'value': '-52.5', 'spread': '59.00', 'groupId': 'OG002'}, {'value': '-66.0', 'spread': '78.10', 'groupId': 'OG003'}]}]}, {'title': '2 Hour Post-dose', 'categories': [{'measurements': [{'value': '-14.0', 'spread': '57.06', 'groupId': 'OG000'}, {'value': '-26.2', 'spread': '40.34', 'groupId': 'OG001'}, {'value': '-65.0', 'spread': '81.34', 'groupId': 'OG002'}, {'value': '-49.9', 'spread': '57.51', 'groupId': 'OG003'}]}]}, {'title': '2.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-10.8', 'spread': '69.18', 'groupId': 'OG000'}, {'value': '-10.6', 'spread': '70.27', 'groupId': 'OG001'}, {'value': '-37.4', 'spread': '79.84', 'groupId': 'OG002'}, {'value': '-18.8', 'spread': '65.83', 'groupId': 'OG003'}]}]}, {'title': '3 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.2', 'spread': '80.54', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '65.55', 'groupId': 'OG001'}, {'value': '-45.2', 'spread': '74.46', 'groupId': 'OG002'}, {'value': '-31.8', 'spread': '81.31', 'groupId': 'OG003'}]}]}, {'title': '4 Hour Post-dose', 'categories': [{'measurements': [{'value': '-20.1', 'spread': '67.37', 'groupId': 'OG000'}, {'value': '-15.9', 'spread': '61.57', 'groupId': 'OG001'}, {'value': '-48.1', 'spread': '99.08', 'groupId': 'OG002'}, {'value': '-44.6', 'spread': '71.37', 'groupId': 'OG003'}]}]}, {'title': '6 Hour Post-dose', 'categories': [{'measurements': [{'value': '-112.1', 'spread': '115.18', 'groupId': 'OG000'}, {'value': '-101.1', 'spread': '94.08', 'groupId': 'OG001'}, {'value': '-127.3', 'spread': '89.62', 'groupId': 'OG002'}, {'value': '-146.5', 'spread': '94.86', 'groupId': 'OG003'}]}]}, {'title': '8 Hour Post-dose', 'categories': [{'measurements': [{'value': '-74.0', 'spread': '95.45', 'groupId': 'OG000'}, {'value': '-38.8', 'spread': '95.45', 'groupId': 'OG001'}, {'value': '-97.8', 'spread': '83.82', 'groupId': 'OG002'}, {'value': '-83.7', 'spread': '88.55', 'groupId': 'OG003'}]}]}, {'title': '12 Hour Post-dose', 'categories': [{'measurements': [{'value': '-24.8', 'spread': '94.78', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '89.18', 'groupId': 'OG001'}, {'value': '-47.3', 'spread': '103.93', 'groupId': 'OG002'}, {'value': '-15.7', 'spread': '93.15', 'groupId': 'OG003'}]}]}, {'title': '16 Hour Post-dose', 'categories': [{'measurements': [{'value': '-61.3', 'spread': '98.99', 'groupId': 'OG000'}, {'value': '-39.9', 'spread': '105.20', 'groupId': 'OG001'}, {'value': '-83.3', 'spread': '99.08', 'groupId': 'OG002'}, {'value': '-94.7', 'spread': '84.41', 'groupId': 'OG003'}]}]}, {'title': '24 Hour Post-dose', 'categories': [{'measurements': [{'value': '-98.8', 'spread': '127.77', 'groupId': 'OG000'}, {'value': '-42.6', 'spread': '106.76', 'groupId': 'OG001'}, {'value': '-74.0', 'spread': '101.40', 'groupId': 'OG002'}, {'value': '-85.1', 'spread': '88.69', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of RR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Effect of Evobrutinib on ECG Parameters: QT Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '395.8', 'spread': '28.44', 'groupId': 'OG000'}, {'value': '393.2', 'spread': '27.84', 'groupId': 'OG001'}, {'value': '394.5', 'spread': '26.29', 'groupId': 'OG002'}, {'value': '396.4', 'spread': '27.77', 'groupId': 'OG003'}]}]}, {'title': '15 Minutes Post-dose', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '6.99', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '6.70', 'groupId': 'OG001'}, {'value': '0.1', 'spread': '6.34', 'groupId': 'OG002'}, {'value': '1.2', 'spread': '8.39', 'groupId': 'OG003'}]}]}, {'title': '30 Minutes Post-dose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '8.71', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '5.61', 'groupId': 'OG001'}, {'value': '-1.7', 'spread': '7.29', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '7.44', 'groupId': 'OG003'}]}]}, {'title': '1 Hour Post-dose', 'categories': [{'measurements': [{'value': '-5.2', 'spread': '8.86', 'groupId': 'OG000'}, {'value': '-2.8', 'spread': '7.99', 'groupId': 'OG001'}, {'value': '3.6', 'spread': '10.74', 'groupId': 'OG002'}, {'value': '-5.0', 'spread': '9.08', 'groupId': 'OG003'}]}]}, {'title': '1.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-8.0', 'spread': '8.12', 'groupId': 'OG000'}, {'value': '-6.0', 'spread': '8.93', 'groupId': 'OG001'}, {'value': '3.2', 'spread': '10.41', 'groupId': 'OG002'}, {'value': '-8.2', 'spread': '11.75', 'groupId': 'OG003'}]}]}, {'title': '2 Hour Post-dose', 'categories': [{'measurements': [{'value': '-4.3', 'spread': '7.63', 'groupId': 'OG000'}, {'value': '-6.9', 'spread': '6.62', 'groupId': 'OG001'}, {'value': '3.5', 'spread': '13.02', 'groupId': 'OG002'}, {'value': '-7.4', 'spread': '10.21', 'groupId': 'OG003'}]}]}, {'title': '2.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-4.5', 'spread': '9.55', 'groupId': 'OG000'}, {'value': '-5.4', 'spread': '9.46', 'groupId': 'OG001'}, {'value': '5.5', 'spread': '11.71', 'groupId': 'OG002'}, {'value': '-4.1', 'spread': '10.14', 'groupId': 'OG003'}]}]}, {'title': '3 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.5', 'spread': '10.58', 'groupId': 'OG000'}, {'value': '-3.6', 'spread': '9.31', 'groupId': 'OG001'}, {'value': '5.3', 'spread': '12.19', 'groupId': 'OG002'}, {'value': '-6.0', 'spread': '12.45', 'groupId': 'OG003'}]}]}, {'title': '4 Hour Post-dose', 'categories': [{'measurements': [{'value': '-5.7', 'spread': '9.95', 'groupId': 'OG000'}, {'value': '-4.4', 'spread': '10.67', 'groupId': 'OG001'}, {'value': '2.4', 'spread': '16.10', 'groupId': 'OG002'}, {'value': '-7.8', 'spread': '10.66', 'groupId': 'OG003'}]}]}, {'title': '6 Hour Post-dose', 'categories': [{'measurements': [{'value': '-19.2', 'spread': '15.98', 'groupId': 'OG000'}, {'value': '-16.9', 'spread': '13.10', 'groupId': 'OG001'}, {'value': '-13.6', 'spread': '13.12', 'groupId': 'OG002'}, {'value': '-22.3', 'spread': '14.43', 'groupId': 'OG003'}]}]}, {'title': '8 Hour Post-dose', 'categories': [{'measurements': [{'value': '-13.7', 'spread': '13.06', 'groupId': 'OG000'}, {'value': '-11.3', 'spread': '13.33', 'groupId': 'OG001'}, {'value': '-8.2', 'spread': '12.25', 'groupId': 'OG002'}, {'value': '-14.2', 'spread': '12.80', 'groupId': 'OG003'}]}]}, {'title': '12 Hour Post-dose', 'categories': [{'measurements': [{'value': '-2.7', 'spread': '14.12', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '13.23', 'groupId': 'OG001'}, {'value': '1.4', 'spread': '14.28', 'groupId': 'OG002'}, {'value': '-1.7', 'spread': '12.04', 'groupId': 'OG003'}]}]}, {'title': '16 Hour Post-dose', 'categories': [{'measurements': [{'value': '-4.1', 'spread': '14.04', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '15.15', 'groupId': 'OG001'}, {'value': '-0.9', 'spread': '13.19', 'groupId': 'OG002'}, {'value': '-8.5', 'spread': '13.26', 'groupId': 'OG003'}]}]}, {'title': '24 Hour Post-dose', 'categories': [{'measurements': [{'value': '-16.3', 'spread': '18.95', 'groupId': 'OG000'}, {'value': '-9.5', 'spread': '13.66', 'groupId': 'OG001'}, {'value': '-8.5', 'spread': '13.92', 'groupId': 'OG002'}, {'value': '-15.8', 'spread': '12.30', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of QT interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Effect of Evobrutinib on ECG Parameters: QTcF Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '389.4', 'spread': '18.08', 'groupId': 'OG000'}, {'value': '388.4', 'spread': '17.88', 'groupId': 'OG001'}, {'value': '389.8', 'spread': '17.28', 'groupId': 'OG002'}, {'value': '390.0', 'spread': '17.58', 'groupId': 'OG003'}]}]}, {'title': '15 Minutes Post-dose', 'categories': [{'measurements': [{'value': '1.6', 'spread': '4.50', 'groupId': 'OG000'}, {'value': '1.6', 'spread': '4.66', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '3.91', 'groupId': 'OG002'}, {'value': '2.8', 'spread': '3.75', 'groupId': 'OG003'}]}]}, {'title': '30 Minutes Post-dose', 'categories': [{'measurements': [{'value': '0.8', 'spread': '5.08', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '3.77', 'groupId': 'OG001'}, {'value': '1.8', 'spread': '5.90', 'groupId': 'OG002'}, {'value': '1.6', 'spread': '4.26', 'groupId': 'OG003'}]}]}, {'title': '1 Hour Post-dose', 'categories': [{'measurements': [{'value': '-1.2', 'spread': '4.49', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '4.62', 'groupId': 'OG001'}, {'value': '8.8', 'spread': '7.14', 'groupId': 'OG002'}, {'value': '1.3', 'spread': '5.16', 'groupId': 'OG003'}]}]}, {'title': '1.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.7', 'spread': '4.50', 'groupId': 'OG000'}, {'value': '-3.8', 'spread': '5.04', 'groupId': 'OG001'}, {'value': '9.8', 'spread': '8.09', 'groupId': 'OG002'}, {'value': '0.2', 'spread': '5.46', 'groupId': 'OG003'}]}]}, {'title': '2 Hour Post-dose', 'categories': [{'measurements': [{'value': '-2.7', 'spread': '3.77', 'groupId': 'OG000'}, {'value': '-3.6', 'spread': '3.98', 'groupId': 'OG001'}, {'value': '11.7', 'spread': '7.92', 'groupId': 'OG002'}, {'value': '-1.1', 'spread': '5.61', 'groupId': 'OG003'}]}]}, {'title': '2.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.3', 'spread': '5.26', 'groupId': 'OG000'}, {'value': '-3.9', 'spread': '4.87', 'groupId': 'OG001'}, {'value': '10.0', 'spread': '6.33', 'groupId': 'OG002'}, {'value': '-1.7', 'spread': '4.52', 'groupId': 'OG003'}]}]}, {'title': '3 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.7', 'spread': '5.89', 'groupId': 'OG000'}, {'value': '-3.4', 'spread': '4.64', 'groupId': 'OG001'}, {'value': '10.8', 'spread': '5.78', 'groupId': 'OG002'}, {'value': '-1.9', 'spread': '5.29', 'groupId': 'OG003'}]}]}, {'title': '4 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.3', 'spread': '5.34', 'groupId': 'OG000'}, {'value': '-2.4', 'spread': '5.80', 'groupId': 'OG001'}, {'value': '8.4', 'spread': '7.03', 'groupId': 'OG002'}, {'value': '-2.0', 'spread': '5.54', 'groupId': 'OG003'}]}]}, {'title': '6 Hour Post-dose', 'categories': [{'measurements': [{'value': '-5.0', 'spread': '7.51', 'groupId': 'OG000'}, {'value': '-4.0', 'spread': '7.07', 'groupId': 'OG001'}, {'value': '3.0', 'spread': '8.24', 'groupId': 'OG002'}, {'value': '-3.4', 'spread': '7.51', 'groupId': 'OG003'}]}]}, {'title': '8 Hour Post-dose', 'categories': [{'measurements': [{'value': '-4.5', 'spread': '5.64', 'groupId': 'OG000'}, {'value': '-6.2', 'spread': '7.41', 'groupId': 'OG001'}, {'value': '4.2', 'spread': '8.00', 'groupId': 'OG002'}, {'value': '-3.4', 'spread': '7.85', 'groupId': 'OG003'}]}]}, {'title': '12 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.2', 'spread': '6.32', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '5.88', 'groupId': 'OG001'}, {'value': '7.2', 'spread': '8.94', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '4.51', 'groupId': 'OG003'}]}]}, {'title': '16 Hour Post-dose', 'categories': [{'measurements': [{'value': '3.6', 'spread': '8.14', 'groupId': 'OG000'}, {'value': '3.8', 'spread': '7.79', 'groupId': 'OG001'}, {'value': '9.6', 'spread': '6.99', 'groupId': 'OG002'}, {'value': '3.7', 'spread': '6.89', 'groupId': 'OG003'}]}]}, {'title': '24 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.8', 'spread': '8.18', 'groupId': 'OG000'}, {'value': '-4.1', 'spread': '6.16', 'groupId': 'OG001'}, {'value': '0.9', 'spread': '6.97', 'groupId': 'OG002'}, {'value': '-4.9', 'spread': '6.05', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of QTcF was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Effect of Evobrutinib on ECG Parameters: QTcP Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '388.2', 'spread': '17.69', 'groupId': 'OG000'}, {'value': '387.5', 'spread': '17.40', 'groupId': 'OG001'}, {'value': '389.1', 'spread': '17.18', 'groupId': 'OG002'}, {'value': '388.9', 'spread': '17.08', 'groupId': 'OG003'}]}]}, {'title': '15 Minutes Post-dose', 'categories': [{'measurements': [{'value': '1.9', 'spread': '5.21', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '5.54', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '4.06', 'groupId': 'OG002'}, {'value': '3.2', 'spread': '3.71', 'groupId': 'OG003'}]}]}, {'title': '30 Minutes Post-dose', 'categories': [{'measurements': [{'value': '0.8', 'spread': '5.51', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '4.57', 'groupId': 'OG001'}, {'value': '2.5', 'spread': '6.65', 'groupId': 'OG002'}, {'value': '1.9', 'spread': '4.32', 'groupId': 'OG003'}]}]}, {'title': '1 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '4.91', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '5.15', 'groupId': 'OG001'}, {'value': '9.8', 'spread': '7.30', 'groupId': 'OG002'}, {'value': '2.5', 'spread': '5.47', 'groupId': 'OG003'}]}]}, {'title': '1.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.1', 'spread': '4.95', 'groupId': 'OG000'}, {'value': '-3.4', 'spread': '5.18', 'groupId': 'OG001'}, {'value': '10.9', 'spread': '8.35', 'groupId': 'OG002'}, {'value': '1.7', 'spread': '5.45', 'groupId': 'OG003'}]}]}, {'title': '2 Hour Post-dose', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '4.06', 'groupId': 'OG000'}, {'value': '-3.1', 'spread': '3.94', 'groupId': 'OG001'}, {'value': '13.0', 'spread': '8.26', 'groupId': 'OG002'}, {'value': '-0.1', 'spread': '5.33', 'groupId': 'OG003'}]}]}, {'title': '2.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.1', 'spread': '5.59', 'groupId': 'OG000'}, {'value': '-3.7', 'spread': '5.20', 'groupId': 'OG001'}, {'value': '10.7', 'spread': '6.57', 'groupId': 'OG002'}, {'value': '-1.3', 'spread': '4.45', 'groupId': 'OG003'}]}]}, {'title': '3 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.7', 'spread': '6.33', 'groupId': 'OG000'}, {'value': '-3.5', 'spread': '4.60', 'groupId': 'OG001'}, {'value': '11.7', 'spread': '5.43', 'groupId': 'OG002'}, {'value': '-1.2', 'spread': '5.18', 'groupId': 'OG003'}]}]}, {'title': '4 Hour Post-dose', 'categories': [{'measurements': [{'value': '-2.9', 'spread': '5.43', 'groupId': 'OG000'}, {'value': '-2.0', 'spread': '5.71', 'groupId': 'OG001'}, {'value': '9.4', 'spread': '6.86', 'groupId': 'OG002'}, {'value': '-1.0', 'spread': '5.65', 'groupId': 'OG003'}]}]}, {'title': '6 Hour Post-dose', 'categories': [{'measurements': [{'value': '-2.6', 'spread': '7.96', 'groupId': 'OG000'}, {'value': '-1.7', 'spread': '7.46', 'groupId': 'OG001'}, {'value': '5.8', 'spread': '8.54', 'groupId': 'OG002'}, {'value': '-0.0', 'spread': '7.63', 'groupId': 'OG003'}]}]}, {'title': '8 Hour Post-dose', 'categories': [{'measurements': [{'value': '-3.0', 'spread': '6.12', 'groupId': 'OG000'}, {'value': '-5.2', 'spread': '7.82', 'groupId': 'OG001'}, {'value': '6.3', 'spread': '8.36', 'groupId': 'OG002'}, {'value': '-1.4', 'spread': '8.29', 'groupId': 'OG003'}]}]}, {'title': '12 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.8', 'spread': '6.20', 'groupId': 'OG000'}, {'value': '-0.9', 'spread': '5.90', 'groupId': 'OG001'}, {'value': '8.2', 'spread': '9.62', 'groupId': 'OG002'}, {'value': '0.3', 'spread': '4.98', 'groupId': 'OG003'}]}]}, {'title': '16 Hour Post-dose', 'categories': [{'measurements': [{'value': '4.9', 'spread': '8.65', 'groupId': 'OG000'}, {'value': '4.5', 'spread': '8.10', 'groupId': 'OG001'}, {'value': '11.3', 'spread': '7.53', 'groupId': 'OG002'}, {'value': '5.8', 'spread': '7.07', 'groupId': 'OG003'}]}]}, {'title': '24 Hour Post-dose', 'categories': [{'measurements': [{'value': '-1.5', 'spread': '8.22', 'groupId': 'OG000'}, {'value': '-3.2', 'spread': '6.86', 'groupId': 'OG001'}, {'value': '2.5', 'spread': '7.33', 'groupId': 'OG002'}, {'value': '-2.9', 'spread': '6.47', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of QTcP was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Effect of Evobrutinib on ECG Parameters: PR Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '166.7', 'spread': '16.59', 'groupId': 'OG000'}, {'value': '170.4', 'spread': '17.93', 'groupId': 'OG001'}, {'value': '167.7', 'spread': '17.73', 'groupId': 'OG002'}, {'value': '167.1', 'spread': '17.99', 'groupId': 'OG003'}]}]}, {'title': '15 Minutes Post-dose', 'categories': [{'measurements': [{'value': '-0.2', 'spread': '4.66', 'groupId': 'OG000'}, {'value': '-1.2', 'spread': '5.29', 'groupId': 'OG001'}, {'value': '-0.8', 'spread': '4.01', 'groupId': 'OG002'}, {'value': '-1.3', 'spread': '4.36', 'groupId': 'OG003'}]}]}, {'title': '30 Minutes Post-dose', 'categories': [{'measurements': [{'value': '0.5', 'spread': '3.72', 'groupId': 'OG000'}, {'value': '2.6', 'spread': '4.37', 'groupId': 'OG001'}, {'value': '-1.2', 'spread': '5.27', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '5.14', 'groupId': 'OG003'}]}]}, {'title': '1 Hour Post-dose', 'categories': [{'measurements': [{'value': '1.1', 'spread': '4.13', 'groupId': 'OG000'}, {'value': '1.2', 'spread': '4.04', 'groupId': 'OG001'}, {'value': '-1.5', 'spread': '7.52', 'groupId': 'OG002'}, {'value': '-0.8', 'spread': '5.11', 'groupId': 'OG003'}]}]}, {'title': '1.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '1.9', 'spread': '5.11', 'groupId': 'OG000'}, {'value': '0.9', 'spread': '5.15', 'groupId': 'OG001'}, {'value': '-1.9', 'spread': '7.41', 'groupId': 'OG002'}, {'value': '-0.9', 'spread': '5.69', 'groupId': 'OG003'}]}]}, {'title': '2 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.9', 'spread': '4.91', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '3.59', 'groupId': 'OG001'}, {'value': '-2.5', 'spread': '8.15', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '5.24', 'groupId': 'OG003'}]}]}, {'title': '2.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.6', 'spread': '4.64', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '5.20', 'groupId': 'OG001'}, {'value': '-3.5', 'spread': '6.49', 'groupId': 'OG002'}, {'value': '-1.4', 'spread': '6.69', 'groupId': 'OG003'}]}]}, {'title': '3 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '5.69', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '5.45', 'groupId': 'OG001'}, {'value': '-3.7', 'spread': '7.42', 'groupId': 'OG002'}, {'value': '-3.0', 'spread': '5.16', 'groupId': 'OG003'}]}]}, {'title': '4 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '7.11', 'groupId': 'OG000'}, {'value': '-1.2', 'spread': '5.01', 'groupId': 'OG001'}, {'value': '-3.6', 'spread': '7.77', 'groupId': 'OG002'}, {'value': '-4.2', 'spread': '4.16', 'groupId': 'OG003'}]}]}, {'title': '6 Hour Post-dose', 'categories': [{'measurements': [{'value': '-9.3', 'spread': '7.52', 'groupId': 'OG000'}, {'value': '-9.4', 'spread': '4.73', 'groupId': 'OG001'}, {'value': '-10.6', 'spread': '8.22', 'groupId': 'OG002'}, {'value': '-11.1', 'spread': '8.48', 'groupId': 'OG003'}]}]}, {'title': '8 Hour Post-dose', 'categories': [{'measurements': [{'value': '-8.3', 'spread': '6.98', 'groupId': 'OG000'}, {'value': '-9.3', 'spread': '6.53', 'groupId': 'OG001'}, {'value': '-9.3', 'spread': '7.30', 'groupId': 'OG002'}, {'value': '-11.1', 'spread': '7.17', 'groupId': 'OG003'}]}]}, {'title': '12 Hour Post-dose', 'categories': [{'measurements': [{'value': '-2.2', 'spread': '7.43', 'groupId': 'OG000'}, {'value': '-3.9', 'spread': '8.28', 'groupId': 'OG001'}, {'value': '-3.6', 'spread': '8.03', 'groupId': 'OG002'}, {'value': '-2.8', 'spread': '6.28', 'groupId': 'OG003'}]}]}, {'title': '16 Hour Post-dose', 'categories': [{'measurements': [{'value': '-2.6', 'spread': '8.70', 'groupId': 'OG000'}, {'value': '-5.2', 'spread': '7.20', 'groupId': 'OG001'}, {'value': '-3.1', 'spread': '7.95', 'groupId': 'OG002'}, {'value': '-4.1', 'spread': '6.25', 'groupId': 'OG003'}]}]}, {'title': '24 Hour Post-dose', 'categories': [{'measurements': [{'value': '-1.0', 'spread': '7.00', 'groupId': 'OG000'}, {'value': '-2.6', 'spread': '6.14', 'groupId': 'OG001'}, {'value': '-0.5', 'spread': '9.38', 'groupId': 'OG002'}, {'value': '-1.2', 'spread': '7.99', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of PR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}, {'type': 'SECONDARY', 'title': 'Effect of Evobrutinib on ECG Parameters: QRS Duration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '31', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Evobrutinib 45mg', 'description': 'Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG001', 'title': 'Evobrutinib 225mg', 'description': 'Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG002', 'title': 'Moxifloxacin 400mg', 'description': 'Participants received single oral dose of Moxifloxacin 400 mg in treatment period 1, 2, 3 or 4 under fasted condition'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received single oral solution of placebo in treatment period 1, 2, 3 or 4 under fasted condition'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '91.7', 'spread': '8.28', 'groupId': 'OG000'}, {'value': '91.8', 'spread': '8.24', 'groupId': 'OG001'}, {'value': '91.7', 'spread': '8.11', 'groupId': 'OG002'}, {'value': '91.0', 'spread': '8.12', 'groupId': 'OG003'}]}]}, {'title': '15 Minutes Post-dose', 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.44', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '1.15', 'groupId': 'OG001'}, {'value': '0.1', 'spread': '1.31', 'groupId': 'OG002'}, {'value': '0.4', 'spread': '1.23', 'groupId': 'OG003'}]}]}, {'title': '30 Minutes Post-dose', 'categories': [{'measurements': [{'value': '0.4', 'spread': '1.25', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '1.41', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '1.22', 'groupId': 'OG002'}, {'value': '0.7', 'spread': '1.44', 'groupId': 'OG003'}]}]}, {'title': '1 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.20', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '1.02', 'groupId': 'OG001'}, {'value': '0.2', 'spread': '1.26', 'groupId': 'OG002'}, {'value': '0.5', 'spread': '1.29', 'groupId': 'OG003'}]}]}, {'title': '1.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.4', 'spread': '1.30', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '1.29', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '1.16', 'groupId': 'OG002'}, {'value': '-0.1', 'spread': '1.15', 'groupId': 'OG003'}]}]}, {'title': '2 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '1.17', 'groupId': 'OG000'}, {'value': '-0.6', 'spread': '1.47', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '1.42', 'groupId': 'OG002'}, {'value': '-0.5', 'spread': '1.60', 'groupId': 'OG003'}]}]}, {'title': '2.5 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '1.29', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '1.64', 'groupId': 'OG001'}, {'value': '-0.2', 'spread': '1.27', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '1.59', 'groupId': 'OG003'}]}]}, {'title': '3 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '1.35', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '1.50', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '1.03', 'groupId': 'OG002'}, {'value': '-0.1', 'spread': '1.35', 'groupId': 'OG003'}]}]}, {'title': '4 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.7', 'spread': '1.41', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '1.71', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '1.70', 'groupId': 'OG002'}, {'value': '0.0', 'spread': '1.53', 'groupId': 'OG003'}]}]}, {'title': '6 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '2.26', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '2.12', 'groupId': 'OG001'}, {'value': '-0.6', 'spread': '1.70', 'groupId': 'OG002'}, {'value': '-0.4', 'spread': '1.98', 'groupId': 'OG003'}]}]}, {'title': '8 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.8', 'spread': '1.99', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '1.78', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '1.82', 'groupId': 'OG002'}, {'value': '0.4', 'spread': '1.97', 'groupId': 'OG003'}]}]}, {'title': '12 Hour Post-dose', 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.95', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '2.14', 'groupId': 'OG001'}, {'value': '0.2', 'spread': '1.45', 'groupId': 'OG002'}, {'value': '0.2', 'spread': '1.85', 'groupId': 'OG003'}]}]}, {'title': '16 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.0', 'spread': '1.91', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '1.74', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '1.90', 'groupId': 'OG002'}, {'value': '0.8', 'spread': '2.08', 'groupId': 'OG003'}]}]}, {'title': '24 Hour Post-dose', 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.93', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '1.22', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '1.31', 'groupId': 'OG002'}, {'value': '0.5', 'spread': '1.43', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of QRS duration was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Sequence 1', 'description': 'Participants received single oral dose of Placebo on Day 1 in fasted state in Period 1, followed by single oral dose of moxifloxacin 400 mg tablet on Day 8 in fasted state in Period 2, followed by 45 mg single dose of oral solution of evobrutinib in fasted state on Day 15 in Period 3, and 225mg single dose of oral solution of evobrutinib in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods'}, {'id': 'FG001', 'title': 'Sequence 2', 'description': 'Participants received single oral dose of moxifloxacin 400 mg tablet on Day 1 in fasted state in Period 1, followed by single oral dose of Evobrutinib 225 mg solution on Day 8 in fasted state in Period 2, followed by single oral dose of Placebo in fasted state on Day 15 in Period 3, and 45 mg of dose of single oral solution of evobrutinib in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods'}, {'id': 'FG002', 'title': 'Sequence 3', 'description': 'Participants received single oral dose of evobrutinib 45 mg solution on Day 1 in fasted state in Period 1, followed by single oral dose of Placebo on Day 8 in fasted state in Period 2, followed by single oral dose of 225 mg evobrutinib solution in fasted state on Day 15 in Period 3, and 400 mg of dose of single oral tablet of moxifloxacin in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods'}, {'id': 'FG003', 'title': 'Sequence 4', 'description': 'Participants received single oral dose of evobrutinib 225 mg solution on Day 1 in fasted state in Period 1, followed by single oral dose of 45 mg evobrutinib solution on Day 8 in fasted state in Period 2, followed by single oral dose of 400 mg moxifloxacin tablet in fasted state on Day 15 in Period 3, and single oral dose of Placebo in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '9'}, {'groupId': 'FG003', 'numSubjects': '9'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '8'}, {'groupId': 'FG003', 'numSubjects': '8'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Participant did not meet all eligibility criteria, ADMISSION DRUG SCREEN POSITIVE', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Participant discontinued prior to first dosing', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '35', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': 'Sequence 1', 'description': 'Participants received single oral dose of Placebo on Day 1 in fasted state in Period 1, followed by single oral dose of moxifloxacin 400 mg tablet on Day 8 in fasted state in Period 2, followed by 45 mg single dose of oral solution of evobrutinib in fasted state on Day 15 in Period 3, and 225mg single dose of oral solution of evobrutinib in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods'}, {'id': 'BG001', 'title': 'Sequence 2', 'description': 'Participants received single oral dose of moxifloxacin 400 mg tablet on Day 1 in fasted state in Period 1, followed by single oral dose of Evobrutinib 225 mg solution on Day 8 in fasted state in Period 2, followed by single oral dose of Placebo in fasted state on Day 15 in Period 3, and 45 mg of dose of single oral solution of evobrutinib in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods'}, {'id': 'BG002', 'title': 'Sequence 3', 'description': 'Participants received single oral dose of evobrutinib 45 mg solution on Day 1 in fasted state in Period 1, followed by single oral dose of Placebo on Day 8 in fasted state in Period 2, followed by single oral dose of 225 mg evobrutinib solution in fasted state on Day 15 in Period 3, and 400 mg of dose of single oral tablet of moxifloxacin in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods'}, {'id': 'BG003', 'title': 'Sequence 4', 'description': 'Participants received single oral dose of evobrutinib 225 mg solution on Day 1 in fasted state in Period 1, followed by single oral dose of 45 mg evobrutinib solution on Day 8 in fasted state in Period 2, followed by single oral dose of 400 mg moxifloxacin tablet in fasted state on Day 15 in Period 3, and single oral dose of Placebo in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '45', 'spread': '7.5', 'groupId': 'BG000'}, {'value': '36', 'spread': '10.4', 'groupId': 'BG001'}, {'value': '41', 'spread': '8.6', 'groupId': 'BG002'}, {'value': '40', 'spread': '11.3', 'groupId': 'BG003'}, {'value': '41', 'spread': '9.6', 'groupId': 'BG004'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '7', 'groupId': 'BG003'}, {'value': '27', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '35', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}]}, {'title': 'White', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '32', 'groupId': 'BG004'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The safety analysis set included all participants who were administered any dose of any study intervention.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2022-12-01', 'size': 12103688, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2025-10-25T03:36', 'hasProtocol': True}, {'date': '2023-02-06', 'size': 1725887, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2025-10-25T03:36', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'OTHER', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 36}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-11-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2023-08-25', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-10-25', 'studyFirstSubmitDate': '2025-10-08', 'resultsFirstSubmitDate': '2025-10-25', 'studyFirstSubmitQcDate': '2025-10-08', 'lastUpdatePostDateStruct': {'date': '2025-11-13', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2025-10-25', 'studyFirstPostDateStruct': {'date': '2025-10-09', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2025-11-13', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2023-08-25', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib", 'timeFrame': 'Baseline and from 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours', 'description': 'A linear mixed-effects model was used to analyze the relationship between evobrutinib and MSC2729909A concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted over the clinical concentration range and at concentrations corresponding to the observed geometric mean Cmax following administration of 45 mg and 225 mg evobrutinib. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.'}], 'secondaryOutcomes': [{'measure': "Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Moxifloxacin", 'timeFrame': 'From 1 hour before any administration until 24 hours post-administration at the following timepoints: -1-hour, 5 min, 10 min, 20 min, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours', 'description': 'A linear mixed-effects model was used to analyze the relationship between moxifloxacin concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'timeFrame': 'Up to 3 months', 'description': 'An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.Therefore, an AE can be any unfavorable and unintended sign (including an abnormallaboratory finding), symptom, or disease temporally associated with the use of amedicinal product, regardless if it is considered related to the medicinal product.Serious AE: AE that resulted in any of the following outcomes: death; life threatening;persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization;congenital anomaly/birth defect. TEAEs are defined as AEs that were reported orworsened on or after start of study drug dosing through the Safety Follow-up Visit.TEAEs included both serious TEAEs and non-serious TEAEs. Treatment related AEs:reasonably related to the study drug/study treatment.'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity', 'timeFrame': 'Up to 3 months', 'description': 'Severity of adverse events (AE) were assessed by the investigator. The Investigator assessed the intensity of each AE and SAE reported during the study and assigned it to 1 of the following categories:\n\n1\\. Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. 2. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 3. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Number of participants with severe adverse events were reported.'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities From Baseline in Safety Laboratory Tests', 'timeFrame': 'Up to Day 29', 'description': 'The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities from baseline were reported. Clinically Significance was decided by investigator.'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities From Baseline in Vital Signs', 'timeFrame': 'Up to Day 29', 'description': 'Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.'}, {'measure': 'Number of Participants With Clinically Significant Changes From Baseline in Electroencephalogram (EEG) and Electrocardiogram (ECG) Findings', 'timeFrame': 'Up to Day 29', 'description': 'The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities were reported. Clinically significance was decided by investigator.'}, {'measure': 'Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) of Evobrutinib', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.'}, {'measure': 'Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Evobrutinib', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Evobrutinib', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.'}, {'measure': 'Time to Reach Maximum Blood Concentration (Tmax) of Evobrutinib', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.'}, {'measure': 'Apparent Terminal Half-life (t1/2) of Evobrutinib', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.'}, {'measure': 'Area Under the Blood-Concentration Time Curve From Time Zero to 24 Hours Post-Dose (AUC 0-24) Of Moxifloxacin', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Moxifloxacin', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.'}, {'measure': 'Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Moxifloxacin', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.'}, {'measure': 'Time to Reach Maximum Blood Concentration (Tmax) of Moxifloxacin', 'timeFrame': 'Pre-dose up to 24 hours post-dose on Days 1, 8, 15, and 22', 'description': 'Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.'}, {'measure': 'Effect of Evobrutinib on ECG Parameters: ECG Mean Heart Rate', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of Heart rate was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.'}, {'measure': 'Effect of Evobrutinib on ECG Parameters: RR Interval', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of RR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.'}, {'measure': 'Effect of Evobrutinib on ECG Parameters: QT Interval', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of QT interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.'}, {'measure': 'Effect of Evobrutinib on ECG Parameters: QTcF Interval', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of QTcF was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.'}, {'measure': 'Effect of Evobrutinib on ECG Parameters: QTcP Interval', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of QTcP was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.'}, {'measure': 'Effect of Evobrutinib on ECG Parameters: PR Interval', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of PR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.'}, {'measure': 'Effect of Evobrutinib on ECG Parameters: QRS Duration', 'timeFrame': 'Baseline, and post-dose at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, and 24 hours', 'description': 'The effect of evobrutinib on baseline-corrected measurements of QRS duration was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['M2951', "Bruton's Tyrosine Kinase", 'Cardiac Repolarization'], 'conditions': ['Healthy']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://clinicaltrials.emdgroup.com/en/', 'label': 'Trial Awareness and Transparency website'}, {'url': 'https://www.merckgroup.com/en/company/contact-us/medinfo-contact-map.html', 'label': 'Medical Information Location Map - Med Info Contacts'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Participants are overtly healthy as determined by medical evaluation, including no clinically significant abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection, or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion\n* Participants have a body weight within 50.0 and 100.0 kilograms (kg) (inclusive) and body mass index (BMI) within the range 19.0 and 30.0 kilograms per square meter (kg/m\\^2) (inclusive)\n* Participants are stable nonsmokers for at least 3 months preceding the first administration of study intervention\n\nExclusion Criteria:\n\n* Participants with history or presence of clinically relevant respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, musculoskeletal, genitourinary, immunological, dermatological, connective tissue, psychiatric (due to rare risk of hallucinations, agitation, and activation of psychosis), and other diseases or disorders, and epilepsy, as determined by medical evaluation\n* Participants with diagnosis of hemochromatosis, Wilson´s disease, alpha 1 antitrypsin deficiency, or any other chronic liver disease including Gilbert's disease will be excluded from the study. Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery within 6 months prior to the first administration of study intervention\n* Participants with history of any malignancy\n* Participants with history of seizures\n* Participants with history of pharmacologically treated psychiatric disease"}, 'identificationModule': {'nctId': 'NCT07214935', 'briefTitle': 'A TQT Study of Effect of M2951 on Cardiac Repolarization', 'organization': {'class': 'INDUSTRY', 'fullName': 'Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany'}, 'officialTitle': 'A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of Evobrutinib on the QTc (Corrected QT) Interval in Healthy Adult Participants', 'orgStudyIdInfo': {'id': 'MS200527_0070'}, 'secondaryIdInfos': [{'id': '2022-002664-78', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment Sequence 1', 'description': 'Participants will receive one of the four interventions in a sequence decided at randomization.', 'interventionNames': ['Drug: Placebo matched to M2951', 'Drug: Moxifloxacin', 'Drug: M2951 Low Dose', 'Drug: M2951 High Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Sequence 2', 'description': 'Participants will receive one of the four interventions in a sequence decided at randomization.', 'interventionNames': ['Drug: Placebo matched to M2951', 'Drug: Moxifloxacin', 'Drug: M2951 Low Dose', 'Drug: M2951 High Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Sequence 3', 'description': 'Participants will receive one of the four interventions in a sequence decided at randomization.', 'interventionNames': ['Drug: Placebo matched to M2951', 'Drug: Moxifloxacin', 'Drug: M2951 Low Dose', 'Drug: M2951 High Dose']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Sequence 4', 'description': 'Participants will receive one of the four interventions in a sequence decided at randomization.', 'interventionNames': ['Drug: Placebo matched to M2951', 'Drug: Moxifloxacin', 'Drug: M2951 Low Dose', 'Drug: M2951 High Dose']}], 'interventions': [{'name': 'Placebo matched to M2951', 'type': 'DRUG', 'description': 'Participants will receive single oral dose of placebo matched to M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.', 'armGroupLabels': ['Treatment Sequence 1', 'Treatment Sequence 2', 'Treatment Sequence 3', 'Treatment Sequence 4']}, {'name': 'Moxifloxacin', 'type': 'DRUG', 'description': 'Participants will receive single oral dose of moxifloxacin in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.', 'armGroupLabels': ['Treatment Sequence 1', 'Treatment Sequence 2', 'Treatment Sequence 3', 'Treatment Sequence 4']}, {'name': 'M2951 Low Dose', 'type': 'DRUG', 'otherNames': ['Evobrutinib', 'MSC2364447C'], 'description': 'Participants will receive single oral low dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.', 'armGroupLabels': ['Treatment Sequence 1', 'Treatment Sequence 2', 'Treatment Sequence 3', 'Treatment Sequence 4']}, {'name': 'M2951 High Dose', 'type': 'DRUG', 'otherNames': ['Evobrutinib', 'MSC2364447C'], 'description': 'Participants will receive single oral high dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.', 'armGroupLabels': ['Treatment Sequence 1', 'Treatment Sequence 2', 'Treatment Sequence 3', 'Treatment Sequence 4']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Neu-Ulm', 'country': 'Germany', 'facility': 'Nuvisan GmbH', 'geoPoint': {'lat': 48.39279, 'lon': 10.01112}}], 'overallOfficials': [{'name': 'Medical Responsible', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}